Simulations Plus teams up with Nvidia to accelerate AI-driven drug modelling
The collaboration will centre on developing GPU-optimised simulation capabilities, introducing AI-assisted tools to support model construction and parameter fitting, and expanding the use of model-informed drug development workflows.
Credit: Bidaala Studio/Shutterstock
Simulations Plus has announced a collaboration with Nvidia aimed at speeding up drug development by combining advanced simulation software with GPU-powered computing and artificial intelligence tools.
The California-based modelling software company said the partnership will focus on improving the speed and scale of scientific workflows used by pharmaceutical researchers, particularly in areas such as quantitative systems pharmacology (QSP) and pharmacokinetics/pharmacodynamics (PK/PD) modelling.
Register for FREE to keep reading
Join 12,000+ scientists, engineers, and IT professionals driving innovation through informatics, HPC, and simulation with:
- Insights into HPC, AI, lab informatics & data
- Curated content for life sciences, engineering & academia
- Access to Breakthroughs: real-world computing success
- Free reports & panels, including the Lab Informatics Guide
- White Papers & software updates for smarter research
Sign up now
Already a member? Log in here
Your data is protected under our privacy policy.
